No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Monte Rosa Therapeutics Reports Q1 2024 Financial Results: A Detailed Overview
Buy Rating Affirmed for Monte Rosa Therapeutics Amidst Promising Drug Pipeline and Stable Financials
Express News | Monte Rosa Therapeutics Expects Its Cash And Cash Equivalents Of $197.8M To Be Sufficient To Fund Planned Operations And Capital Expenditures Into The First Half Of 2026
Express News | Monte Rosa Therapeutics Q1 2024 GAAP EPS $(0.53) Beats $(0.59) Estimate
Monte Rosa Therapeutics | 10-Q: Quarterly report
Monte Rosa Therapeutics Corporate Presentation Release